


BIOVENDOR LTD

**UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER 2019**



Company Registration Number: 09345657

BIOVENDOR LTD

**UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019**

CONTENTS	PAGES
Company information	1
Balance sheet	2 to 3
Notes to the financial statements	4 to 6

BIOVENDOR LTD

**COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2019**

DIRECTORS

Mrs H E Church

Dr V Ruzicka

resigned 1 September 2019

Mr M Kostka

appointed 1 September 2019

SECRETARY

The company does not have an appointed secretary

REGISTERED OFFICE

184b Park Drive

Milton Park

Milton

Abingdon

Oxon

OX14 4SE

COMPANY REGISTRATION NUMBER

09345657 England and Wales

BIOVENDOR LTD**BALANCE SHEET
AS AT 31 DECEMBER 2019**

	Notes	2019 £	2018 £
FIXED ASSETS			
Investments	5	1,439,028	1,439,028
CURRENT ASSETS			
Debtors	6	334	-
Cash at bank and in hand		822	882
		<u>1,156</u>	<u>882</u>
CREDITORS: Amounts falling due within one year	7	<u>1,237,150</u>	<u>1,265,449</u>
NET CURRENT LIABILITIES		<u>(1,235,994)</u>	<u>(1,264,567)</u>
NET ASSETS		<u>203,034</u>	<u>174,461</u>
CAPITAL AND RESERVES			
Called up share capital		1	1
Distributable profit and loss account		203,033	174,460
		<u>203,034</u>	<u>174,461</u>
SHAREHOLDER'S FUNDS		<u>203,034</u>	<u>174,461</u>

BIOVENDOR LTD

**BALANCE SHEET
AS AT 31 DECEMBER 2019**

These accounts have been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006 and in accordance with the provisions of FRS 102 Section 1A - small entities.


For the financial year ended 31 December 2019 the company was entitled to exemption from audit under section 479A of the Companies Act 2006.

Members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

As permitted by S444 (5A) of the Companies Act 2006 the directors have not delivered to the Registrar a copy of the company's Profit and Loss Account and Statement of Retained Earnings or Directors' Report.

Signed on behalf of the board of directors



Mrs H E Church
Director

Date approved by the board: 16/6/2020

BIOVENDOR LTD

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

1 GENERAL INFORMATION

Biovendor Ltd is a private company limited by shares and incorporated in England and Wales. Its registered office is:

184b Park Drive
Milton Park
Milton
Abingdon
Oxon
OX14 4SE

The financial statements are presented in Sterling, which is the functional currency of the company.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation of financial statements

These financial statements have been prepared in accordance with applicable United Kingdom accounting standards, including Financial Reporting Standard 102 Section 1A smaller entities 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' ('FRS 102') and the Companies Act 2006.

Investments

Investments in subsidiaries are shown at cost less accumulated impairment losses.

Financial Instruments

The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

Financial assets are measured at cost and are assessed at the end of each reporting period for objective evidence of impairment. Where objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

The impairment loss for financial assets measured at cost is measured as the difference between an asset's carrying amount and the best estimate, which is an approximation, of the amount that the company would receive for the asset if it were to be sold at the reporting date.

Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is an enforceable right to set off the recognised amount and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Debtors

Short term debtors are measured at transaction price, less any impairment.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued...)

Creditors

Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and subsequently at amortised cost.

Taxation

Taxation expense represents the aggregate amount of current tax and deferred tax recognised in the reporting period.

A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods based on current tax rates and laws. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period.

Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other taxable profits.

Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Current and deferred tax assets and liabilities are not discounted.

3 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

No significant accounting estimates and judgements have had to be made by the directors in preparing these financial statements.

4 EMPLOYEES

The average number of persons employed by the company (including directors) during the year was:

	2019	2018
Average number of employees	<u>2</u>	<u>2</u>

BIOVENDOR LTD**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019****5 FIXED ASSET INVESTMENTS**

	Investment in subsidiary £
Cost	
At 1 January 2019	1,439,028
At 31 December 2019	<u>1,439,028</u>
Net book value	
At 1 January 2019	<u>1,439,028</u>
At 31 December 2019	<u>1,439,028</u>

6 DEBTORS

	2019 £	2018 £
Other debtors	334	-

7 CREDITORS: Amounts falling due within one year

	2019 £	2018 £
Amounts owed to group undertakings	1,234,751	1,263,889
Accruals and deferred income	2,399	1,560
	<u>1,237,150</u>	<u>1,265,449</u>

8 PARENT COMPANY

The company is a subsidiary undertaking of BioVendor Laboratorní Medicína a.s., a company incorporated in Czech Republic, whose registered office is Karasek 1767/1, 621 00 Brno, Czech Republic.

9 ULTIMATE PARENT COMPANY

The largest group company in which the results of the company are consolidated is that headed by ConsilTech a.s., a company incorporated in Czech Republic, whose registered office is Purkyňova 2121/3, Nové Město (Prague 1), 110 00 Prague, Czech Republic.

10 GROUP ACCOUNTS

The company can claim intermediate party exemption from the obligation to prepare and deliver group accounts as it is itself a subsidiary.